MassChallenge Startups Create Impact

2,928

Startups Accelerated

$8.6B

Funding Raised

$3.6B

Revenue Generated

186K+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
MyoGene Bio

MyoGene Bio is developing therapies for muscle diseases starting with a gene editing therapy, MyoDys45-55, for Duchenne muscular dystrophy, a devastating fatal muscle wasting disease. We have demonstrated proof-of-efficacy that MyoDys45-55 can restore the protein otherwise lacking in Duchenne, expected to significantly improve the disease course and lifespan for about half of all Duchenne patients. MyoGene Bio is currently working to complete preclinical development to translate this therapy.
MyoGene Bio is developing cutting edge therapies for muscle diseases, starting with a gene editing therapy for Duchenne muscular dystrophy.

Connect with MyoGene Bio

MyoGene Bio

2021

2021 Silver RI-98

Sub industry

Therapeutics (Pharma / Biotech)

Mission

Our mission is to equip bold entrepreneurs to disrupt the status quo and to create meaningful change.